Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00299507 · ClinicalTrials.gov registry record · Phase 3
Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)
A Phase 3 study of Macular Degeneration, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
- 1
- Study location
NCT00299507 is a Phase 3 study of Macular Degeneration that has completed, run by Alcon Research. The registered enrollment target is 240 participants, above the 170-participant average among 26 other Macular Degeneration trials with a reported enrollment target (41% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00299507, a Phase 3 study of Macular Degeneration, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study was to evaluate the effect of the dose concentration and administration frequency of Anecortave Acetate (AA) on visual acuity (VA) and lesion size when administered by posterior juxtascleral depot (PJD) every 3 months (AA 15 mg) or 6 months (AA 15 mg, AA 30 mg) in patients with exudative age-related macular degeneration (AMD).
Conditions Studied
Interventions
- DRUG Anecortave Acetate Sterile Suspension, 30 mg/mL
- DRUG Anecortave Acetate Sterile Suspension, 60 mg/mL
- OTHER Anecortave Acetate Vehicle
Study Locations (1)
Texas
- Alcon Study Sites - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2005-03 |
| Est. Completion | 2008-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00299507
The ClinicalTrials.gov registry entry for NCT00299507 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 170-participant average among 26 other Macular Degeneration trials with a reported enrollment target (41% higher). The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Macular Degeneration appearing as the primary indexed condition, and to 3 interventions - of which Anecortave Acetate Sterile Suspension, 30 mg/mL is the first listed.
NCT00299507 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00299507 about?
NCT00299507 is a clinical study titled "Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)". The purpose of this study was to evaluate the effect of the dose concentration and administration frequency of Anecortave Acetate (AA) on visual acuity (VA) and lesion size when administered by posterior juxtascleral depot (PJD) every 3 months (AA 15 mg) or 6 months (AA 15 mg, AA 30 mg) in patients ...
What is the current status of trial NCT00299507?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2005-03. Estimated completion is 2008-04.
What conditions does trial NCT00299507 study?
This clinical trial studies the following conditions: Macular Degeneration.
What interventions are being tested in trial NCT00299507?
The interventions under investigation include: Anecortave Acetate Sterile Suspension, 30 mg/mL (DRUG), Anecortave Acetate Sterile Suspension, 60 mg/mL (DRUG), Anecortave Acetate Vehicle (OTHER).
Who is sponsoring clinical trial NCT00299507?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00299507 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD
COMPLETED · Phase 3
-
A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD
COMPLETED · Phase 3
-
An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD
COMPLETED · Phase 3
-
Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration
COMPLETED · Phase 3
-
Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)
COMPLETED · Phase 3
-
Factors in Learning And Plasticity: Macular Degeneration
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.